Originally published by our sister publication Pharmacy Practice News
By Karen Blum
People with diabetes treated with glucagon-like peptide-1 (GLP-1) agonists were 20% less likely to experience venous thromboembolism (VTE) than similar patients who took dipeptidyl peptidase-4 (DPP-4) inhibitors, regardless of their weight status, according to new research (abstract 701) presented at the 2024 American Society of Hematology Annual Meeting & Exposition, in San Diego.